FDA Wants To Lengthen Review Time For Some Prior Approval Supplements
Executive Summary
FDA wants to lengthen the goal for action on prior-approval manufacturing supplements as part of the PDUFA V reauthorization, but industry does not appear too willing to budge.
You may also be interested in...
PDUFA V: FDA Relaxes Pre-Submission Meeting Requirement
Sponsors may have negotiated a four-month reprieve for the required pre-submission meeting in the proposed new application review system expected to be implemented with PDUFA V.
PDUFA V: FDA Relaxes Pre-Submission Meeting Requirement
Sponsors may have negotiated a four-month reprieve for the required pre-submission meeting in the proposed new application review system expected to be implemented with PDUFA V.
FDA-EMA-TGA Joint Inspection Program To Be Permanent; Other Collaborations Expand
FDA, the European Medicines Agency and Australian Therapeutic Goods Administration intend to make permanent a pilot program allowing for joint facility inspections in what would be another step toward more U.S. reliance on foreign regulator and third-party data and a reduction in inspection burden.